GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Palantir Bioceuticals IFAN · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2015

Net income

−$2.4m

FY2014FY2015

Free cash flow

−$667,503

FY2014FY2015

Shareholders' equity

$3.6m

FY2014FY2015

Income statement

Fiscal years

FY2015FY2014
Gross profit−$24,772—
Research and development$186,068$186,068
Operating income−$2.3m−$42,798
Net income−$2.4m−$41,798
Diluted earnings per share-0.03-0.00

Balance sheet

At each fiscal year end

FY2015FY2014
Total assets$5.0m$281,141
Cash and short-term investments$137,846—
Total liabilities$1.4m$310,708
Debt$475,879$146,187
Shareholders' equity$3.6m−$29,567
Shares outstanding87m80m

Cash flow

Fiscal years

FY2015FY2014
Cash from operations−$595,003−$92,493
Capital spending−$72,500−$30,000
Free cash flow−$667,503−$122,493

Latest quarters

By quarter end

Feb 2022May 2016Feb 2016Nov 2015Aug 2015May 2015Feb 2015Nov 2014
Revenue—$268,294$36—————
Gross profit—$268,294$36—————
Operating income−$62,500−$444,769−$688,499−$1.0m−$255,044−$592,861−$1.3m−$165,083
Net income−$62,500−$662,351−$496,119−$1.4m−$278,926−$595,627−$1.3m−$165,083
Diluted earnings per share-0.00-0.01-0.01-0.02-0.00-0.01-0.01-0.00
Total assets—$4.1m$4.3m$4.7m$5.0m$5.0m$5.0m$282,668
Cash and short-term investments—$135,109$46,245$90,381$137,846$255,352$14,705$17,941
Debt—$1.2m$1.1m$884,642$475,879$223,223$5,000$264,518
Shareholders' equity—$1.7m$2.1m$2.5m$3.6m$3.8m$4.1m−$531,822

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return2300%11420%1974%-90%1178%1381%317%5589%-79%11%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 140-for-1 split · 3 Sept 2014

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.